Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Recap by typeshit. Full story at Dr. Kevin Joseph, DO.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
A woman with four triglyceride-driven pancreatitis episodes came off insulin and had none for 12 months. The authors stress it shows association, not cause.
Ahead of GTA 6, Zelnick told Business Insider he skips untested peptides and leans on sleep, walking and not smoking. He also took a shot at David Sinclair.
Coroner David Ryan found Norton had been taking double his prescribed dose and urged Australia's TGA to tighten rules on peptides, limiting them to clinical trials.
Loading…